Skip to main content

Owens & Minor to Attend Key Investor Conferences

Tipranks - Wed Dec 3, 2025

TipRanks Cyber Monday Sale

The latest update is out from Owens & Minor ( (OMI) ).

On December 2, 2025, Owens & Minor announced that its management team will participate in two upcoming investor conferences, including the Citi 2025 Global Healthcare Conference in Miami and the Bank of America Leveraged Finance Conference in Boca Raton. This participation reflects the company’s ongoing efforts to engage with investors and stakeholders, potentially impacting its market positioning and investor relations.

The most recent analyst rating on (OMI) stock is a Sell with a $2.50 price target. To see the full list of analyst forecasts on Owens & Minor stock, see the OMI Stock Forecast page.

Spark’s Take on OMI Stock

According to Spark, TipRanks’ AI Analyst, OMI is a Underperform.

Owens & Minor’s overall stock score is low due to significant financial challenges, bearish technical indicators, and unattractive valuation metrics. While the earnings call highlighted some strategic initiatives, the company’s current financial instability and market momentum issues are the most significant factors impacting the score.

To see Spark’s full report on OMI stock, click here.

More about Owens & Minor

Owens & Minor, Inc. is a Fortune 500 global healthcare solutions company that provides essential products and services supporting care from hospitals to homes. With over 100 years of experience, the company, along with its affiliated brands Apria, Byram, and HALYARD, serves patients, providers, and communities worldwide, employing more than 20,000 people.

Average Trading Volume: 2,245,284

Technical Sentiment Signal: Sell

Current Market Cap: $206.5M

See more insights into OMI stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.